Removing barriers to global pandemic influenza vaccination

Biosecurity and Bioterrorism

Volumn 4, Issue 2, 2006, Pages 168-175

  Gronvall, Gigi Kwik ^a   Borio, Luciana L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

EUROPEAN UNION; GENETICS; GOVERNMENT REGULATION; HEALTH; HUMAN; IMMUNOLOGY; INFLUENZA; JAPAN; PATENT; PREVENTIVE HEALTH SERVICE; REVIEW; UNITED STATES;

EUROPEAN UNION; GOVERNMENT REGULATION; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA, HUMAN; INTELLECTUAL PROPERTY; JAPAN; UNITED STATES; VACCINES; WORLD HEALTH;

EID: 33746078819     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2006.4.168     Document Type: Review

References (37)

1. World Health Organization. H5N1 Avian Influenza-First Steps Towards Development of a Human Vaccine. Geneva: World Health Organization; August 12, 2005. Available at: http://www.who.int/csr/disease/avian_influenza/ statement_2005_08_12/en/print.html Accessed May 1, 2006.
2. World Health Organization, Department of Communicable Disease Surveillance and Response. Vaccines for Pandemic Influenza: Informal Meeting of WHO, Influenza Vaccine Manufacturers, National Licensing Agencies, and Government Representatives on Influenza Pandemic Vaccines. Geneva: World Health Organization; November 11-12, 2004. Available at: http://www.who.int/csr/ disease/influenza/meeting2004_11_08/en/ Accessed May 1, 2006.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Geneva: ICH Secretariat; 2005. Available at: www.ich.org. Accessed November 28, 2005.
4. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis Jun 15 2003;36(12):1552-1561.
5. Sanofi Pasteur Media Center. Sanofi pasteur signs contract with French government to produce pandemic influenza vaccine; influenza vaccine leader sanofi pasteur contributes to French pandemic preparedness [press release]. Lyon, France: sanofi pasteur; November 10, 2005. Available at: http://www.sanofipasteur.com/sanofi-pasteur/front/templates/vaccinations-travel- health-vaccine-aventis-pasteur. jsp?&lang=EN&codeRubrique= 13&codePage=grippe_ pandemique Accessed May 1, 2006.
6. Abraham J, Reed T. Progress, innovation and regulatory science in drug development: the politics of international standard-setting. Soc Stud Sci Jun 2002;32(3):337-369.
7. Danzon PM, Pereira NS, Tejwani SS. Vaccine supply: a cross-national perspective. Health Aff (Millwood) May-Jun 2005;24(3):706-717.
8. Branch SK. Guidelines from the International Conference on Harmonisation (ICH). J Pharm Biomed Anal Aug 10 2005;38(5):798-805.
9. Coleman MS, Sangrujee N, Zhou F, Chu S. Factors affecting U.S. manufacturers' decisions to produce vaccines. Health Aff (Millwood) May-Jun 2005;24(3):635-642.
10. Drezner DW. Globalization, harmonization, and competition: the different pathways to policy convergence. Journal of European Public Policy October 2005;12(5):841-859.
11. U.S. Food and Drug Administration. FDA News: PDA approves new influenza vaccine for upcoming flu season [press release]. Rockville, Md: U.S. Food and Drug Administration; August 31, 2005. Available at: http://www. fda.gov/bbs/topics/news/2005/NEW01227.html Accessed May 1, 2006.
12. U.S. Food and Drug Administration. Fluarix BLA Clinical Review. Rockville, Md: U.S. Food and Drug Administration; August 17, 2005. Available at: http://www.fda.gov/Cber/review/inflgla083105r1_p1.pdf Accessed May 1, 2006.
13. GlaxoSmithKline. Key Features: Why Fluarix? Research Triangle Park, NC: GlaxoSmithKline; undated. Available at: http://www.fluarix.com/hcp/keyFeatures. htm. Accessed April 7, 2006.
14. Hearings before the Committee on Government Reform in the United States House of Representatives, Washington, DC, November 17, 2004 (statement of Lester M. Crawford, DVM, PhD, Acting Commissioner of Food and Drugs). Available at: http://www.fda.gov/ola/2004/vaccines1117. html Accessed May 1, 2006.
15. U.S. Food and Drug Administration. FDA announces rapid response team to combat pandemic (avian) flu: team will boost agency's efforts to expedite manufacturing of Tami-flu and new drugs to treat avian flu [press release]. Rockville, Md: U.S. Food and Drug Administration; October 24, 2005. Available at: http://www.fda.gov/bbs/t opics/NEWS/2005/NEW01248.html Accessed May 1, 2006.
16. European Medicines Agency (EMEA). Questions and answers on EU action on avian influenza and flu pandemic preparedness [press release]. Brussels: European Medicines Agency; August 25, 2005. Available at: http://europa.eu.int/ rapid/pressReleasesAction.do?reference=‴ MEMO/05/283&format= HTML&aged=0&language= EN&guiLanguage=en Accessed May 1, 2006.
17. European Medicines Agency (EMEA). European Medicines Agency receives first pandemic influenza vaccine application [press release]. Brussels: European Medicines Agency; January 6, 2006. Available at: http://www. biotech-intelligence.com/html/html/c5cc89909eba1b 278677b9351f189ad0.html Accessed May 1, 2006.
18. European Medicines Agency (EMEA). European Medicines Agency receives second application for human pandemic influenza vaccine [press release]. Brussels: European Medicines Agency; February 24, 2006. Available at: http://www.emea.eu.int/pdfs/general/direct/pr/3532206en. pdf Accessed May 1, 2006.
19. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26(1):4-29.
20. Hungarian H5N1 vaccine not to be submitted to European drug authority: researchers. Richmond, UK: EU Business; March 17, 2006. Available at: http://www.eubusiness.com/Pharma/060317115749.ans2jmhw. Accessed April 4, 2006.
21. Ildiko V, Jankovics I. H5N1 vaccine in Hungary: development, evaluation, production. Paper presented at: WHO Meeting on Development and Evaluation of Influenza Pandemic Vaccines; November 2-3, 2005; Geneva. http://www.who.int/ vaccine_research/diseases/influenza/V isontai.pdf Accessed May 1, 2006.
22. AFP. Romania wants to produce Hungarian bird flu vaccine. Yahoo/News March 20, 2006. Available at: http://fullcoverage.yahoo.com/s/afp/20060320/ hl_afp/health fluromaniahungaryvaccine_060320143227;_ylt=A86.Ilu wpiNEsxkApQuTvyIi;_ylu=X3oDMTBiMW04NW9m BHNlYwMlJVRPUCUl. Accessed April 4, 2006.
23. World Health Organization, Department of Communicable Disease Surveillance and Response. Production of pilot lots of inactivated influenza vaccine from reassortants derived from avian influenza viruses; Interim biosafety risk assessment [press release]. Geneva: World Health Organization; November, 2003. Available at: http://www.who.int/csr/resources/publications/ influenza/WHO_CDS_CSR_R MD_2003_5/en/Accessed May 1, 2006.
24. World Health Organization, Department of Communicable Disease Surveillance and Response, Global Influenza Programme. WHO Guidance on Development of Influenza Vaccine Reference Viruses by Reverse Genetics. Geneva: World Health Organization; 2005. Available at: http://www.who.int/csr/resources/ publications/influenza/WHO_ CDS_CSR_GIP_2005_6.pdf Accessed May 1, 2006.
25. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines (draft guidance). Rockville, Md: U.S. Food and Drug Administration; March 2006. Available at: http://www.fda.gov/cber/gdlns/ panfluvac.pdf Accessed May 1, 2006.
26. Gagneten S. Pandemic influenza vaccines: FDA preparedness activities. Paper presented at: NVAC; April 20, 2005. Available at: www.hhs.gov/nvpo/ meetings/PowerPoints/Gagneten42005NVACPIWGfl.ppt Accessed May 1, 2006.
27. Goodman JL. Meeting the challenge of pandemic vaccine preparedness: an PDA perspective. Paper presented at: John R. LaMontagne Symposium on Pandemic Influenza Research, 2005; Washington, DC. Available at: http://www.iom.edu/ Object.File/Master/26/333/0.pdf Accessed May 1, 2006.
28. Wood JM. Developing vaccines against pandemic influenza. Philos Trans R Soc Land B Biol Sci Dec 29 2001; 356(1416):1953-1960.
29. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med Mar 30 2006; 354(13):1343-1351.
30. Chiron News. Chiron announces promising data from clinical study of adjuvanted avian influenza vaccine; results confirm previous clinical studies: Chiron's MF59 adjuvant significantly enhances immune response [press release]. Emeryville, Calif: Chiron; October 28, 2005. Available at: http://phx.corporate- ir.net/phoenix.zhtml?c=105850& p=irol-newsArticle_Print&ID= 774795&highlight= Accessed May 1, 2006.
31. MedImmune. MedImmune to collaborate with National Institutes of Health to develop pandemic influenza vaccine: attenuated, live intranasal vaccine may provide broader protection and help facilitate immunization during pandemic outbreak [press release]. Gaithersburg, Md: MedImmune; September 28, 2005. Available at: http://phx. corporate-ir.net/phoenix.zhtml?c=83037&p= irolinvestornewsArticle&ID=762012&highlight= Accessed May 1, 2006.
32. CSL Limited. Preventive Steps and Vaccines. Melbourne, Australia: CSL Ltd; 2005. Available at: http://www. csl.com.au/Preventive_Vaccines. asp#vaccine_available. Accessed November 29, 2005.
33. Canada to launch avian flu vaccine trial. CTV.ca. 20 April, 2005. Available at: www.ctv.ca/servlet Accessed May 1, 2006.
34. Branswell H. Feds sign H5N1 flu vaccine deal. Canoe network (Quebecor media). November 28, 2005. Available at: http://cnews.canoe.ca/CNEWS/Canada/ 2005/11/28/pf-1327876.html Accessed May 1, 2006.
35. Solvay. Vaccines: the first line of defence. Brussels: Solvay; 2005. Available at: http://www.solvay-influenza.com/influenzapandemic/vaccines/0, 31980-2-0,00.htm. Accessed April 12, 2006.
36. Solvay. Solvay Pharmaceuticals will supply Norway with special vaccines in the event of an influenza pandemic [press release]. Brussels: Solvay; February 17, 2005.
37. H. Permatasari S, Wahyudi S. Baxter to help Indonesia develop human vaccine for avian flu. Bloomberg News November 28, 2005. Available at: http://www.bloomberg. com/apps/news?pid=10000080&sid=aIYi8KUIMlfA& refer=asia Accessed May 1, 2006.